Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 08, 2025 16:30 ET | Source: Exicure, Inc.

Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced...
November 07, 2025 16:00 ET | Source: Exicure, Inc.

Exicure, Inc. Reports Third Quarter 2025 Financial Results

Exicure, Inc. Reports Third Quarter 2025 Financial Results
November 03, 2025 09:00 ET | Source: Exicure, Inc.

New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that...
October 06, 2025 07:00 ET | Source: Exicure, Inc.

Exicure Highlights Recent Achievements and Near-term Strategic Priorities

Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug...
October 11, 2016 08:00 ET | Source: Exicure, Inc.

Exicure Announces Positive Phase 1 Data for Topical Anti-TNF Compound AST-005 in Patients with Mild to Moderate Psoriasis

SKOKIE, Ill., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Exicure, a pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today announced results...
April 26, 2016 07:00 ET | Source: Exicure, Inc.

Exicure Announces Dosing of First Patient in Phase 1 Trial for the Treatment of Chronic Plaque Psoriasis

SKOKIE, Ill., April 26, 2016 (GLOBE NEWSWIRE) -- Exicure, a pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today announced the dosing...
February 12, 2016 11:57 ET | Source: Exicure, Inc.

Exicure Co-Founder Awarded Prestigious Dan David Prize

SKOKIE, Ill., Feb. 12, 2016 (GLOBE NEWSWIRE) -- Exicure is pleased to announce that Chad A. Mirkin, Ph.D., co-founder and director of Exicure, has been named the recipient of the 2016 Dan David...
October 15, 2015 06:00 ET | Source: Exicure, Inc.

Exicure Co-Founder Awarded Inaugural Sackler Prize

SKOKIE, Ill., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Exicure is pleased to announce that Chad A. Mirkin, Ph.D., co-founder and director of Exicure, has been named the inaugural recipient of the Raymond and...
April 22, 2015 16:01 ET | Source: Exicure, Inc.

AuraSense Therapeutics Announces Publication of Preclinical Data Demonstrating Immuno-Modulation by its Proprietary Spherical Nucleic Acid Platform

SKOKIE, Ill., April 22, 2015 (GLOBE NEWSWIRE) -- AuraSense Therapeutics, the pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today...
February 04, 2015 10:36 ET | Source: Exicure, Inc.

AuraSense Therapeutics Adds to Series C Financing

SKOKIE, Ill., Feb. 4, 2015 (GLOBE NEWSWIRE) -- AuraSense Therapeutics, the pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today...